426225-91-4

Upstream product

• 426225-90-3 (1S,3R)-1-Hydroxy-3-triphenylmethoxy-4-cyclopentene 
• 60410-16-4 (1R,4S)-4-hydroxy-2-cyclopentene-1-yl acetate 
• 120520-91-4 (1R,4S)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol 
• 115074-49-2 (1R,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-cyclopentene-1-yl acetate 

Downstream Products

• 426225-92-5 (1S,3R)-1-(2-dimethylmalonyl)-3-triphenylmethoxy-4-cyclopentene 
• 660439-53-2 ((1R,4R)-4-Trityloxy-cyclopent-2-enyl)-acetic acid methyl ester 
• 426225-93-6 (1R,4S)-4-hydroxycyclopent-2-en-1-essigsaeure-methylester 

Relevant academic research and scientific papers

Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases

The invention concerns pharmaceutical compositions that contain a compound or compounds that can effectively regulate the activity of Type 5 Adenylyl Cyclase and methods for treatment of neurological diseases and disorders, as well as motor function loss

Metal coordination-based inhibitors of adenylyl cyclase: Novel potent P-site antagonists

The adenylyl cyclases (ACs) are a family of intracellular enzymes associated with signal transduction by virtue of their ability to convert ATP to cAMP. The catalytic mechanism of this transformation proceeds through initial binding of ATP to the so-calle

Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof

The present invention relates to derivatives and analogues of adenine, which inhibit adenylyl cyclase activity. The present invention also relates to a method of preventing and inhibiting a patient's fibroproliferative vasculopathy following vascular injury or a vascular surgical operation which includes administering to the patient, an effective amount of a compound according to the invention subsequent to a vascular injury, or subsequent to a vascular surgical operation, for one to two weeks after the injury or surgical operation, effective to treat or prevent a patient's fibroproliferative vasculopathy such as chronic allograft rejection or vascular restenosis following vascular trauma. The present invention also relates to a method for measuring the inhibition of adenylyl cyclase activity and a method for treating congestive heart failure.